Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

Sander Kelderman(The Netherlands Cancer Institute), Bianca Heemskerk(The Netherlands Cancer Institute), Harm van Tinteren(The Netherlands Cancer Institute), Rob R. H. van den Brom(University Medical Center Groningen), Geke A.P. Hospers(University Medical Center Groningen), Alfonsus Johannes Maria van den Eertwegh(Amsterdam UMC Location Vrije Universiteit Amsterdam), Ellen Kapiteijn(Leiden University), Jan Willem B. de Groot(Bergman Clinics), Patricia M.M.B. Soetekouw(University Medical Center), Rob L. Jansen(University Medical Center), E. Fiets(Medisch Centrum Leeuwarden), Andrew Furness(Royal Marsden NHS Foundation Trust), Alexandra Renn(Royal Marsden NHS Foundation Trust), Marcin Krzystanek(Technical University of Denmark), Zoltán Szállási(Technical University of Denmark), Paul Lorigan(The Christie Hospital), Martin Gore(Royal Marsden NHS Foundation Trust), Ton N. Schumacher(The Netherlands Cancer Institute), John B.A.G. Haanen(The Netherlands Cancer Institute), James Larkin(Royal Marsden NHS Foundation Trust), Christian U. Blank(The Netherlands Cancer Institute)
Cancer Immunology Immunotherapy
March 7, 2014
Cited by 300Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis